Objective: Published data have shown that microRNAs (miRNAs) could play a potential role as diagnostic and prognostic indicators in cancers. Data for the predictive value of microRNA-155 are inconclusive VSports手机版. The aim of the present analysis was therefore to evaluate the role of miR-155 in prognosis for patients with a variety of carcinomas. .

Methods: Relevant studies were identified by searching PubMed and EMBASE. Data were extracted from studies comparing overall survival (OS), recurrence-free survival (RFS) or cancer-specific survival (CSS) in patients with carcinoma with higher miR-155 expression and those with lower levels. The pooled hazard ratios (HRs) and 95% confidence intervals (CIs) of miR-155 for clinical outcome were calculated. V体育安卓版.

Results: A total of 15 studies were included. The pooled hazard ratio (HR) for OS of higher miR-155 expression in cancerous tissue was 1. 89 (95% CI: 1. 20-2. 99, P =0. 006), which could markedly predict poorer survival in general cancer. For RFS/CSS, elevated miR-155 was also associated with poor prognosis of cancer (HR= 1. 50, 95% CI: 1. 10-2. 05, P = 0. 01). On subgroup analysis, the pooled HR for OS in non-small cell lung cancer (NSCLC) was 2. 09 (95% CI: 0. 68-6. 41, P > 0. 05), but for RFS/CSS was 1. 28 (95% CI: 1 V体育ios版. 05-1. 55, P = 0. 015), with statistical significance; the pooled HRs for OS and RFS/CSS in digestive system neoplasms were 3. 04 (95% CI: 1. 48-6. 24, P =0. 003) and 2. 61 (95% CI: 1. 98-3. 42, P<0. 05), respectively. .

Conclusions: The results indicated that the miR-155 expression level plays a prognostic role in patients with cancer, especially NSCLCs and digestive system carcinomas. VSports最新版本.